Immunosuppressive therapy in interstitial lung diseases and immunologically mediated pneumonitis;Immunsuppressive Therapie bei interstitiellen Lungenerkrankungen und immunologisch vermittelten Pneumonitiden

Internist

Volumn 38, Issue 6, 1997, Pages 553-561

  Muller Quernheim J ^a   Dalhoff, K ^b   Schnabel, A ^b  

^a RESEARCH CENTER BORSTEL   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

COLLAGEN DISEASE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTRAVENOUS DRUG ADMINISTRATION; PNEUMONIA; REVIEW;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COLLAGEN DISEASES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; SARCOIDOSIS, PULMONARY; VASCULITIS;

EID: 0030997381     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00002645     Document Type: Review

References (31)

1. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729-735
2. Boomars KA, Wagenaar SS, Mulder PGH, Velzen Blad H, van den Bosch JMM (1995) Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis. Thorax 50:1087-1092
3. Costabel U (1990) Medikamentöse Lungenveränderungen in der Rheumatologie. Z Rheumatol 49:284-290
4. Eiser AR, Shanies HM (1994) Treatment of Lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 37:428-431
5. Gilbert S, Steinbrech DS, Landas SK, Hunninghake GW (1993) Amounts of angiotensin-converting enzyme mRNA reflect the burden of granulomas in granulomatous lung disease. Am Rev Respir Dis 148:483-486
6. Gross WL (1991) Vaskulitiden der Lunge. Internist 32:622-630
7. Gross WL (1997) Stadienadaptierte Therapie generalisierter Autoimmunerkrankungen und der systemischen Vaskulitiden. Internist 38
8. Hanson D, Winterbauer RH, Kirtland SH, Wu R (1995) Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 108:305-310
9. Haworth SJ, Savage COS, Carr D, Hughes JMB, Rees AJ (1985) Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. Br Med J 290:1775-1778
10. Homolka J, Lorenz J, Zuchhold HD, Müller-Quernheim J (1992) Evaluation of soluble CD14 and serum neopterin as serum parameters of inflammatory activity of pulmonary sarcoidosis. Clin Investig 70:909-916
11. Hunninghake G, Kalica A (1995) Approaches to the treatment of pulmonary sarcoidosis. Am J Respir Crit Care Med 151:915-918
12. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, et al. (1994) Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med 149:893-898
13. Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M (1989) Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44:280-288
14. Leatherman JW, Davies SF, Hoida IJR (1984) Alveolar hemorrhage syndromes: Diffuse microvascular lung hemorrhage in immune and idiopathic disorders. Medicine 63:343-361
15. Meyer A, Buhl R, Kampf S, Magnussen H (1995) Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 152:1055-1066
16. Meyer A, Buhl R, Magnussen H (1994) The effect of oral N-acetylcysteine on lung glutathione levels in idopathic pulmonary fibrosis. Eur Respir J 7:431-436
17. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR (1991) Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 46:592-595
18. Müller-Quernheim J, Sarkoidose. In: Kruck E, Kaufmann W, Bünte H, Gladtke E, Tölle R ed. Therapie - Handbuch. München: Urban & Schwarzenberg, 1989:465-470
19. Müller-Quernheim J (1996) Klinische und immunbiologische Betrachtungen zur entzündlichen Aktivität der Sarkoidose. Pneumologie 50:40-48
20. Peters S, McDougall J, Douglas W, Coles D, DeRemee R (1993) Colchicine in the treatment of pulmonary fibrosis. Chest 103:101-104
21. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Hutchinson J, Pardee NE, Winterbauer RH (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144:291-296
22. Schnabel A, Gross WL (1994) Pulmonale Manifestationen der Wegenerschen Granulomatose - Klinische Korrelate granulomatöser und vaskulitischer Lungenveränderungen. Arthritis und Rheuma 14:28-37
23. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838-844
24. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA (1994) Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 37:1290-1296
25. Strausz J, Müller-Quernheim J, Ferlinz R (1989) Serumspiegel des sezernierten Interleukin-2 Rezeptor als ein Aktivitätsparameter der Sarkoidose. Dtsch med Wschr 114:744-749
26. Turner-Warwick MB, Burrows B, Johnson A (1980) Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 35:593-599
27. Vallence AK, Lynch III JP, McCune WJ (1995) Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis. Curr Op Rheumatol 7:174-182
28. van Oortegem K, Wallaert B, Marquette C, Ramon P, Perez T, Lafitte J, Tonnel A (1994) Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 7:1950-1957
29. Wells AU, Hansell DM, Rubens MD (1993) The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 148:1076-1082
30. Wise RA Pulmonary complications in collagen vascular disease. In: Lynch III JP, DeRemee RA ed. Immunologically mediated pulmonary diseases. Philadelphia: Lippincott Company, 1991:40-88
31. Zabel P, Entzian P, Dalhoff K, Schlaak M (1997) Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med (in press)